We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
Read MoreHide Full Article
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD - Free Report) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49. This represents a strong year-to-date return of approximately 19.9%, better than the S&P 500’s 9%.
For the majority of the last three months, the company’s share price has outperformed the Zacks classified Medical/Dental-Supplies sub-industry. The stock has rallied 23.7%, outshining the sub-industry’s gain of 6.6%. Notably, the stock has a market cap of $1.46 billion.
Taking the stable performance of the stock into consideration, we expect CONMED to gain more ground in the coming quarters. The company’s positive long-term growth of 8.5% also raises optimism.
The stock currently has a Zacks Rank #3 (Hold).
Growth Catalysts
Strong Prospects in the Niche Space: CONMED has been gaining prominence in the minimally invasive surgery markets as a large percentage of the company’s products are designed for such procedures. Per a report by the Markets And Markets, the minimally invasive surgical instruments market is forecasted to reach a worth of $21.47 billion by 2021 at a CAGR of 9.1%.
The general surgery segment of the company witnessed stellar gains, registering a 9.7% increase at constant currency (cc) in the last reported quarter.
Broad Product Spectrum: CONMED offers a broad line of surgical products. The company’s product pipeline consists of several new devices including three new sports medicine products, three endomechanical offerings, a new electrosurgical council and the latest 2D Arthroscopy video system. With increased product offerings, the company can accelerate its top line.
Impressive First-Quarter Numbers: CONMED reported stellar first-quarter 2017 results, crushing the Zacks Consensus Estimate on both the counts. Revenues increased 3% year over year to $180 million, while adjusted earnings improved 26.7%.
In terms of product category, sales of single-use products increased 4% at cc to $149.8 million. Coming to the capital products, sales inched up 2.4% at cc to $36.8 million.
Guidance Upbeat: An upbeat guidance instills our confidence in the stock. For the full year, CONMED expects sales growth in the band of 1% to 3% at cc. The company projects adjusted earnings per share in the range of $1.85 to $1.95.
Favorable Estimate Revision Trend:CONMED’s estimate revision trend looks promising at the moment. The estimates for the full year increased 0.5% to $1.90 over the last two months, as one analyst moved north and one went south.
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Notably, Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy) while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 87.7%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock posted a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 81.2%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD - Free Report) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49. This represents a strong year-to-date return of approximately 19.9%, better than the S&P 500’s 9%.
For the majority of the last three months, the company’s share price has outperformed the Zacks classified Medical/Dental-Supplies sub-industry. The stock has rallied 23.7%, outshining the sub-industry’s gain of 6.6%. Notably, the stock has a market cap of $1.46 billion.
Taking the stable performance of the stock into consideration, we expect CONMED to gain more ground in the coming quarters. The company’s positive long-term growth of 8.5% also raises optimism.
The stock currently has a Zacks Rank #3 (Hold).
Growth Catalysts
Strong Prospects in the Niche Space: CONMED has been gaining prominence in the minimally invasive surgery markets as a large percentage of the company’s products are designed for such procedures. Per a report by the Markets And Markets, the minimally invasive surgical instruments market is forecasted to reach a worth of $21.47 billion by 2021 at a CAGR of 9.1%.
The general surgery segment of the company witnessed stellar gains, registering a 9.7% increase at constant currency (cc) in the last reported quarter.
Broad Product Spectrum: CONMED offers a broad line of surgical products. The company’s product pipeline consists of several new devices including three new sports medicine products, three endomechanical offerings, a new electrosurgical council and the latest 2D Arthroscopy video system. With increased product offerings, the company can accelerate its top line.
Impressive First-Quarter Numbers: CONMED reported stellar first-quarter 2017 results, crushing the Zacks Consensus Estimate on both the counts. Revenues increased 3% year over year to $180 million, while adjusted earnings improved 26.7%.
In terms of product category, sales of single-use products increased 4% at cc to $149.8 million. Coming to the capital products, sales inched up 2.4% at cc to $36.8 million.
Guidance Upbeat: An upbeat guidance instills our confidence in the stock. For the full year, CONMED expects sales growth in the band of 1% to 3% at cc. The company projects adjusted earnings per share in the range of $1.85 to $1.95.
Favorable Estimate Revision Trend:CONMED’s estimate revision trend looks promising at the moment. The estimates for the full year increased 0.5% to $1.90 over the last two months, as one analyst moved north and one went south.
CONMED Corporation Price and Consensus
CONMED Corporation Price and Consensus | CONMED Corporation Quote
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Notably, Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy) while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 87.7%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock posted a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 81.2%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>